Agoracom Blog Home

Posts Tagged ‘psychedelics’

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:28 AM on Saturday, January 22nd, 2022

The Roundup

A weekly summary of Novamind news and media

Novamind Closes Arizona Acquisition

We are pleased to announce that, further to our press release dated December 23, 2021, we have closed our acquisition of Arizona-based Foundations for Change, Inc., a mental health practice specialized in ketamine-assisted psychotherapy.

“We’re thrilled to welcome the team from Foundations,” commented Novamind CEO and Director, Yaron Conforti. “The Acquisition is an exciting opportunity for Novamind to expand the reach of our clinic network, bringing our model for innovative mental healthcare to a new market in Arizona.”

With the closing of the Acquisition, Foundations founder Jeff Edelman, MSN, APRN, PMHNP-BC, PMHCNS-BC, assumes the role of Medical Director at the Peoria and Phoenix clinic locations.

Mr. Edelman commented: “Joining Novamind is the right fit for our team and aligns with our mission to provide innovative and compassionate mental healthcare. I would like to thank our patients, partners and community for their ongoing support over the years. We look forward to integrating our team and operations with Novamind and benefiting from its deep expertise and infrastructure as we continue to serve a growing patient population.”

Read the full release here.

January 18, 2022

Novamind to Participate in Citi’s Psychedelic Drug Video Call Series

We are pleased to announce our participation in Citi’s Psychedelic Drug Video Call Series to be held virtually on January 25, 2022.

Neena Bitritto-Garg, Vice President Research Analyst, Biotech, at Citi, will host Novamind’s Chief Executive Officer, Yaron Conforti and Chief Medical Officer, Reid Robison, MD, MBA, for a fireside chat at 10:00 AM ET.

“Novamind has an established track record as a leader in commercializing psychedelic medicine and other innovative mental health therapies through a growing network of clinics and hosting an exciting pipeline of clinical trials for major drug developers,” said Mr. Conforti. “I look forward to introducing Citi’s clients to Novamind and expanding our relationships with a global base of institutional investors.”

To register for the call, please contact your Citi representative directly.
 

January 20, 2022

View all press releases

January 18, 2022

Can Psychedelics Change Your Personality?

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison explore whether or not psychedelic medicine can change your personality. They discuss the following: alter states for altered traits, “ego” and how psychedelic medicine can lead to personality changes, and much more.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

January 14, 2022

Psychedelic Therapies Continue to Be Seen as Big Trend in Mental Health Treatment

In the latest issue of Mental Health Weekly, Chief Medical Officer Dr. Reid Robison discusses the benefits and barriers of psychedelic treatment and weighs in on the progress of MDMA & psilocybin research and legislative activities in the US.

View all media

Two Thirds of Physicians Surveyed Believe Psilocybin Therapy Has Potential Benefit for Patients With Treatment-Resistant Depression

Perceptions on the potential of psilocybin therapy are shifting in the medical community, according to a recent COMPASS Pathways-sponsored survey. “Severe mental illnesses, such as treatment-resistant depression, have affected too many people in society for too long. Physicians are looking for new approaches to accelerate the healing process, particularly for patients for whom current therapies have failed.” 

MAPS Publishes Open Science Approach to Synthesizing MDMA

A new study by Jay Nair and colleagues from MAPS PBC tries to answer the question of how psychedelic substances will be produced. This is an important step and still, “Many open questions remain about the legal framework that needs to materialize, who will distribute the medicines, and who will be qualified to provide the treatment.” Dr. Robison sat down with Mental Health Weekly for similar conversation.

How Western Medicine Can Adapt to Psychedelic-Assisted Psychotherapy

Lucid News’ Itzhak Beery explores the role of shamanism in Western medicine. “Some psychotherapists feel pressured to offer this type of healing to their clients, who have heard about these magical treatments and hope for a short cut to relief. Most facilitators do not acknowledge the element of spirit or the unseen world.” We’ve also explored this question (and more) in a previous episode of the Psychedelic Frontiers Podcast. Listen to it again here.

For further information, email us: 
[email protected]

We’re hiring!
Check out current opportunities to join our growing team.

Was this email forwarded to you?
Subscribe to our weekly newsletter

VIDEO – Novamind (NM : CSE) Opens 6th Integrative Psychiatry Clinic, Anticipates 65,000 Visits to Clinic Network This Year

Posted by AGORACOM-JC at 8:53 AM on Thursday, September 30th, 2021

Earlier today Novamind Inc. (NM : CSE) (NVMDF: OTCQB) (HN2: FSE) opened its sixth integrative psychiatry clinic. The “Murray Clinic” also serves as Novamind’s third clinical research site, further strengthening the Company’s capabilities for serving drug developers via multiple sites and access to a large patient population.  

The Company anticipates 65,000 visits to its clinics this year. 

Yaron Conforti, CEO and Director, “Bringing cost-effective and innovative psychedelic therapies to market requires a large base of diverse candidates and the expertise to safely and effectively run complex clinical trials in the right environment. We continue to build on our model’s proven track record through the expansion of our clinics and research sites, and we expect to scale this unique operating model into additional states in the near term.” 

Sit back, relax and watch this powerful interview with Yaron Conforti, CEO and Director of Novamind.  

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:19 AM on Saturday, September 25th, 2021

A weekly summary of Novamind news and media, including the announcement of our inclusion in the NYSE Listed AdvisorShares Psychedelics ETF and more.

September 21, 2021

Burnout and the wounded healer​

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Dr. Paul Thielking. Paul is a psychiatrist, zen practitioner, and Chief Scientific Officer at Novamind. They discuss healthcare provider burnout and other unique challenges of being in the helping/healing professions.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

View all media

Novamind Announces Inclusion in NYSE Listed AdvisorShares Psychedelics ETF​

We are pleased to announce that we have been included in the AdvisorShares Psychedelics ETF trading on the NYSE under the ticker “PSIL” (the “ETF”).

PSIL is the first U.S.-listed, actively managed exchange traded fund to deliver dedicated investment exposure to psychedelics. PSIL seeks long-term capital appreciation by investing in the rapidly evolving psychedelics space, offering exposure to companies which the ETF’s portfolio manager views as leading the way in this nascent industry. The ETF currently includes 22 psychedelics companies. 

“The inclusion of Novamind in the AdvisorShares Psychedelics ETF is an important achievement for our Company,” commented Yaron Conforti, CEO and Director of Novamind. “Our clinics and clinical research sites are growing rapidly, and we are pleased to be recognized as a leading company in the emerging psychedelics sector.” 

Additional information on the ETF can be found here.

September 20, 2021

Novamind to Present at Benzinga Healthcare Conference​

Novamind to be featured in panel discussion on the disruptive potential of psychedelic medicine in mental healthcare

We will participate in the Benzinga Healthcare Small Cap Conference taking place virtually on September 29-30, 2021.

Novamind’s CEO and Director, Yaron Conforti, will join a panel of industry leaders for a discussion titled, “Addressing Mental Health through Emerging Therapies” on Thursday, September 30 at 12:35 PM EST.

Following the panel, from 1:15 PM to 1:30 PM EST, Mr. Conforti will deliver a presentation to update investors on the Company’s rapidly growing network of psychiatry clinics and clinical research sites focused on psychedelic medicine. A short Q&A session will follow.

For more information about the event and to register for free, visit: www.benzinga.com/events/small-cap/healthcare/

September 23, 2021

Novamind Announces DTC Eligibility for its Common Shares​

We are pleased to announce that our common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the U.S.

The DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through DTC are considered ‘DTC eligible’. This electronic method of clearing securities speeds up the receipt of stock and cash and accelerates the settlement process for investors and brokers. 

“We are pleased to have become DTC eligible. Investors will benefit from the accelerated settlement process and ability to trade Novamind shares through a wide range of U.S. brokerage firms,” said Yaron Conforti, Chief Executive Officer and Director of Novamind. “This is an important step towards increased liquidity for our stock and building a strong presence for Novamind in the U.S. capital markets.”

September 24, 2021

View all press releases

Mental Health, With a Side of Psychedelics?

A recap of some of the most promising psychedelic drugs for mental health and some of the trailblazers paving the way for the psychedelic revolution. “Sleep, exercise, therapy and antidepressants are some of the top remedies prescribed to assist the 1 in 4 Americans who struggle with mental health issues. But while these are all critical and effective tools, are they enough?”

Psychedelics Are a Billion-Dollar Business, and No One Can Agree Who Should Control It

Novamind’s business model was structured to be drug agnostic. We want to be able to provide the best possible therapies for our clients, regardless of what therapies they end up needing. It’s why we’re a champion for increasing access to all psychedelics. In this article, Shayla Love covers how those interested in psychedelics are learning to work together for the greater good. 

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:22 AM on Saturday, September 18th, 2021

A weekly summary of Novamind news and media, including the announcement of our selection as a research site for Karuna Therapeutics.

September 14, 2021

What Is Psycholytic Ketamine Assisted Psychotherapy?

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by returning guest, Vhari Macbeth to discuss psycholytic ketamine-assisted psychotherapy (KAP).

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

View all media

Novamind to Serve as Research Site for Karuna Therapeutics Late-Stage Clinical Trial

We are pleased to announce that our wholly owned subsidiary, Cedar Clinical Research has been selected as a research site for a clinical trial sponsored by Karuna Therapeutics, Inc., a clinical-stage neuroscience biopharmaceutical company

The phase III study will evaluate the investigational therapy KarXT for the treatment of schizophrenia, a serious and potentially disabling condition affecting approximately 20 million people worldwide.

Dr. Reid Robison, Novamind’s Chief Medical Officer and Principal Investigator at CCR said, “We need more innovation in this field and I’m hopeful to see compounds like KarXT that have new ways of acting on the brain and the potential for improved efficacy and side effect profiles.”

September 13, 2021

View all press releases

Legalising Illicit Therapies: Why Psychedelics Could Be The Most Important Mental Health Breakthrough Of The 21st Century

As psychedelics continue to break free from the stigma surrounding them, more and more people are seeing the promise these drugs have in changing the way we treat mental health. “Recent trials are showing that psychedelics are proving not only successful but also incredibly effective when stacked up against traditional forms of treatment, with one recent trial reporting that they are up to four times more effective than antidepressants.”

The DEA Seeks To Increase Federal Production Limits For Psilocybin And Marijuana Research

In a big step forward for psychedelic research, the DEA is set to increase limits for psilocybin. From the DEA: “DEA firmly believes in supporting regulated research of schedule I controlled substances.” We look forward to increased research and have a dedicated psychedelic contract research organization (CRO) in Cedar Clinical Research, capable of studying promising new treatments.

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

Was this email forwarded to you?
Subscribe to our weekly newsletter

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:54 AM on Saturday, September 11th, 2021

A weekly summary of Novamind news and media, including the announcement of our uplisting to the OTCQB Market and much more.

September 7, 2021

Treating Trauma with Psychedelic-Assisted Psychotherapy

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Hannah Cross to discuss how psychedelic-assisted psychotherapy is used to treat trauma.

August 31, 2021

Treating Eating Disorders with Ketamine-Assisted Psychotherapy

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss how ketamine-assisted psychotherapy is used to treat eating disorders

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

View all media

Novamind Uplists to OTCQB Venture Market

We pleased to announce our common shares have been approved for trading under the ticker symbol “NVMDF” on the OTCQB® Venture Market, a U.S. trading platform operated by the OTC Markets Group, Inc.

“With this listing, we look forward to expanding Novamind’s presence in the U.S. and deepening our relationships with a broad base of institutional and retail investors.” said Yaron Conforti, CEO and Director.

September 9, 2021

Novamind to Present at H.C. Wainwright 23rd Annual Global Investment Conference

CEO and Director, Yaron Conforti, will present the Company’s business model focused on growing a national network of psychiatry clinics and clinical research sites to rapidly scale access to psychedelic medicine.

Learn more about the Conference and register to schedule a one-on-one meeting with Novamind’s management here.

September 8, 2021

View all press releases

The Worldview-Changing Drugs Poised to Go Mainstream

BBC Future covers the experience, culture and future of psychedelics and “what might follow if psychedelics become mainstream.” It’s a popular theme in this week’s roundup: what the world will look like after the psychedelic revolution. “Psychedelics offer something that few other things can: an experience well beyond what our everyday reality could conceive or expect.” With such life changing drugs and therapies becoming available, there’s no doubt the future will look a lot different.

Neurocognitive Effects of Ketamine for Depression Examined

This article delivers more positive news about ketamine and esketamine, which we currently use in our Cedar Psychiatry clinics. Learn more about how we use these powerful drugs here. “Use of ketamine and esketamine for their antidepressant effects does not seem to have harmful neurocognitive effects in individuals with treatment-resistant depression, according to a review published online Aug. 5 in the Harvard Review of Psychiatry.”

Psychedelic Treatments Are Here, But Doctors Aren’t Prepared

Rick Doblin and Jennifer Ouyang Altman lay out the potential risks of not having standardized psychedelic education for providers. It’s a problem that will arise as psychedelics continue to move into the mainstream. It’s one reason why education is such a big component of our mission to increase access to psychedelic medicine. On the Psychedelic Therapy Frontiers podcast, we cover topics across the spectrum from trip-sitting to treating trauma with psychedelic-assisted psychotherapy. Another way we’re helping address this issue is by creating psychedelic treatment protocols, sharing best-in-class techniques and procedures with the wider population. Learn more here.

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

Was this email forwarded to you?
Subscribe to our weekly newsletter

VIDEO – Biomind Labs (BMND : NEO) Is Developing The Next Generation of Medicines For The 21st Century – The Pharmaceutical Side of Psychedelics

Posted by AGORACOM-JC at 4:40 PM on Wednesday, August 25th, 2021
Biomind Labs Inc. Completes Reverse Take-Over Transaction | Business Wire

Alejandro Antalich, CEO of Biomind. “We, both, are driven by innovation. At Biomind, our objective is to change the course of medicine by assisting doctors in potentially saving more lives and providing a better quality of life to millions of people suffering from addiction, chronic pain, depression, anxiety, and other mental health disorders.

Biomind Labs is Developing the next generation of medicines for the 21st century … the pharmaceutical side of psychedelics

THE PROBLEM

● Depression and anxiety cost the global economy US$ 1 trillion each year

  • ~ 20% of the world’s children and adolescents have a mental health condition
  • Suicide is the second leading cause of death among 15-29 year-olds
  • 13% rise in mental health conditions & substance use disorders in last decade (to 2017)
  • Mental health conditions now cause 1 in 5 years lived with disability

#Psychedelics are going to go through a parabolic, paradigm shifting growth in the next 5 years because of their ability to treat anxiety and depression amongst other things

More than 80% of the global population prefers natural products as sources of new drug candidates …

and that is good because Biomind’s vertical integration approach – Transforming natural psychotropic compounds into pharmaceuticals  – creating drug therapies that harness the medicinal power of natural psychedelic compounds

1 indication is already in Phase 2 … 3 indications in Phase 2 by end 2021 … 3 in Phase 3 by end 2022.

Sit back, relax and watch this powerful interview with Alejandro Antalich, Chief Executive Officer of Biomind Labs.

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:17 AM on Saturday, July 31st, 2021

A weekly summary of Novamind news and media, including the announcement of the opening of our fifth location in Draper, Utah.

OPINION July 27, 2021

The Art and Science of Psychedelic Trip-Sitting

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison, Dr. Steve Thayer, and Derick Moody, discuss the art and science of psychedelic trip-sitting.

Visit us at psychedelictherapyfrontiers.com to learn more, subscribe and catch up on previous episodes you may have missed.

FEATURES July 28, 2021

Potential for Exponential Increase in Healing

Gaining insurance coverage for off-label ketamine treatment of depression could help exponentially more people in their healing journeys. Off-label medicine isn’t covered by insurance.

“Our health care system does acknowledge and allow us to use medicines off-label. Probably 20 percent or more of all prescriptions are given that way.” – Novamind Chief Medical Officer Dr. Reid Robison

View all media

Novamind Opens 5th Location Specialized in Integrative Psychiatry for Patients with Treatment-Resistant Conditions

We are pleased to announce the completed the construction of a new clinic focused on integrative psychiatric care and clinical research in Draper, Utah. With the opening of the New Clinic, Novamind is on track to open four new locations in Utah by September 2021, doubling the size of its network to eight clinics.

“We are on a mission to reduce suffering and optimize wellness and are committed to shaping the future of psychedelic medicine in a responsible and accessible way,” said Dr. Reid Robison, Novamind’s Chief Medical Officer.

July 29, 2021

View all press releases

Back to the future: Psychedelic drugs in psychiatry

In an article for Harvard Health, Peter Grinspoon, MD, covers how psychedelics work, evidence for using psychedelics medicinally and the pros and cons. It’s an interesting read given his personal history with psychedelics, which dates back to when he was 14 and reading “Psychedelic Drugs Reconsidered.” He remembers the book urging “an open-minded reappraisal about the therapeutic potential of this class of drugs.” Anyone involved in psychedelics knows that not all conversations on the topic are open-minded. It’s why part of the mission to provide safe, legal access to psychedelics also includes an educational component. The more we can destigmatize psychedelics, the faster we can continue to push the renaissance forward. 

Psychedelic trips could soon be part of therapy — here’s what those sessions will look like

Have you ever wondered what psychedelic therapy looks like? This article provides an insight into that process. “You don’t just get thrown into it,” (Jennifer) Mitchell says. “It’s not Burning Man or something. It’s very thoughtful.” And it’s something we take very seriously at our Cedar Psychiatry clinics. We recently posted a blog about psychedelics and safety considerations. Read it here.

Follow @novamind_inc on Instagram

 
 

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:55 AM on Saturday, July 3rd, 2021

A weekly summary of Novamind news and media, including the announcement of a new podcast hosted by Dr. Steve Thayer and Dr. Reid Robison.

OPINION June 30, 2021

How to Integrate a Psychedelic Experience into Everyday Life

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison and Dr. Steve Thayer discuss how to integrate a psychedelic experience into everyday life.

OPINION June 30, 2021

Psychedelics and the Inner Healing Intelligence

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison and Dr. Steve Thayer are joined by Derick Moody, PA-C, to discuss the role that the inner healing intelligence plays in psychedelic medicine.

OPINION June 30, 2021

Spirituality and the Psychedelic Renaissance

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison and Dr. Steve Thayer discuss the historically messy relationship between spirituality and modern psychiatry and the role that psychedelics are playing in a spiritual renaissance.

View all media

Novamind Launches Psychedelic Therapy Frontiers Podcast

The Podcast is hosted by Novamind’s Dr. Stephen Thayer, Clinical Director, Education & Training and Dr. Reid Robison, Chief Medical Officer. Weekly Podcast episodes feature conversations between Dr. Thayer and Dr. Robison about issues that are of special interest to the psychedelic medicine and research community.

“Psychedelics are the next frontier of psychiatric medicine, and we’re helping professionals learn more about our specialized practice with actionable information. The need for specialized tools in mental healthcare has never been greater,” said Dr. Thayer.

June 30, 2021

View all press releases

I Was Paralyzed by Severe Depression. Then Came Ketamine.

Zoe Boyer writes about her lifelong struggle with depression: “Over the years I tried every available treatment. I stayed in psychiatric hospitals, underwent years of therapy and tried a pharmacy’s worth of antidepressants, but my condition never improved. One day, I stumbled across an article on the use of ketamine as a promising treatment for severe, unresponsive depression.” After four sessions, everything changed. “When my brother got his first pair of glasses, he marveled that he could see individual leaves on trees. Ketamine felt a lot like that. To be in awe of simple pleasures felt like reason enough to live, and I was overcome with a quiet revelation: this is what it means to be content.” Zoe’s story is similar to many who have had life changing experiences with Ketamine. We see it every day at our Cedar Psychiatry clinics. This video shares the stories of just a few of the thousands of patients we’ve treated.

Bay Area Lawmaker’s Proposal To Decriminalize Psychedelics In California Gains Momentum

How one state senator’s bill to decriminalize psilocybin, MDMA, LSD, DMT, mescaline and ibogaine is gaining steam in California. Former army rangers and marine corps veterans are quoted about how psychedelics offered them something they found nowhere else: hope and lasting change. “I will say this unequivocally psychedelics have, and will, save veteran lives.”

Follow @novamind_inc on Instagram

 
 

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

VIDEO: XPhyto Therapeutics $XPHY.ca $XPHYF Three Divisions Firing On All Cylinders As They Move From The Lab to the Clinic $NGM.ca $SONA.ca $HBP.ca $MIR.ca $IPA.ca

Posted by AGORACOM-Eric at 4:41 PM on Tuesday, May 4th, 2021
company

XPhyto Therapeutics $XPHY.ca $XPHYF Signs German Distribution, Storage and Logistics Agreement for 25-Minute COVID-19 PCR Test $NGM.ca $SONA.ca $HBP.ca $MIR.ca $IPA.ca

Posted by AGORACOM-Eric at 8:21 AM on Wednesday, April 21st, 2021
http://blog.agoracom.com/wp-content/uploads/2021/01/XPHYTO-70-x-70.jpg

XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that it has entered into an agreement (the “Agreement”) with an established German pharmaceutical wholesaler and service provider (the “Distributor”) for the distribution, storage and logistics of XPhyto’s diagnostic products in Germany. The Agreement secures XPhyto a full-service distribution partner for its 25-minute SARS-CoV-2 (COVID-19) RT-PCR test system (“Covid-ID Lab”). Covid-ID Lab is registered within the European Union as a commercial in vitro diagnostic (CE-IVD) test.

Pursuant to the Agreement, the Distributor will distribute, store and deliver Covid-ID Lab test kits according to the product specifications and all applicable regulations to XPhyto’s customers. In addition, the Distributor will provide the documentation and fulfillment of storage obligations, the fulfillment of reporting and notification obligations, and the processing of any returned products. The obligations and services to be rendered under the Agreement satisfy all of the logistical and regulatory requirements for the commercial sale of COVID-ID Lab in Germany.

“With this agreement, we have secured a strong partner with an established medical distribution network throughout Germany. This is an exciting and critical step towards commercial sales of COVID-ID Lab,” said Hugh Rogers, CEO and Director of XPhyto. “The Company’s commercialization strategy is focused on the German market for initial product launch and the creation of robust and sustainable sales.”

Covid-ID Lab is a multiplex viral RNA probe kit based on the reverse transcriptase-polymerase chain reaction (RT-PCR) method. Covid-ID Lab requires only a single 20-minute PCR thermal cycle for assay performance without prior RNA extraction as part of the sample preparation. Many widely available standard PCR instruments are suitable to run the test. Results are collected after the PCR cycle via easy-to-read optical indicator strips on a simple fluidics platform. The elimination of RNA extraction for sample preparation reduces cross-contamination risk and minimizes the need for lab materials and trained personnel. The rapid results, minimal laboratory equipment, and ease of use are expected to translate into reduced operating costs, greater convenience and portability.

XPhyto is currently in discussions with various potential customers, distribution and wholesale partners as well as potential licensees. The sales launch in Europe is targeted for April 2021. The Company will provide further information and updates in due course.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.

About XPhyto Therapeutics Corp.

XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

Read More:https://agoracom.com/ir/XphytoTherapeutics/forums/discussion/topics/759431-xphyto-signs-german-distribution-storage-and-logistics-agreement-for-25-minute-covid-19-pcr-test/messages/2312832#message